Crown Bioscience International operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Crown Bioscience International with three other
companies in this sector in Taiwan:
sales of 853.68 million Taiwanese Dollars [US$28.56 million]
Taigen Biopharmaceuticals Holdings Ltd
(553.21 million Taiwanese Dollars [US$18.51 million]
of which 100%
was Medical Development), and
Unicocell Biomed Co Ltd
(1.41 billion Taiwanese Dollars [US$47.13 million]
of which 98%
During the year ended December of 2017, sales at
Crown Bioscience International were 2.24 billion Taiwanese Dollars (US$74.90 million).
increase of 13.3%
versus 2016, when the company's sales were 1.98 billion Taiwanese Dollars.
This was the fourth straight year of sales growth at Crown Bioscience International.